Andrew Dhawan, MD, DPhil, FRCPC
Associate Staff
Location: Cleveland Clinic Main Campus
Research
The Dhawan lab develops, validates, and implements biomarkers for neuro-oncologic and neuro-genetic diseases. These biomarkers are critical to improving the care for patients with neurological diseases such as glioblastoma, which lack cures or treatments that are effective in the long-term. By developing biomarkers for neurologic diseases, we hope to diagnose these conditions earlier, estimate prognosis more accurately, identify when treatments are and are not working and improve how clinical trials are run. Neurologists use signs and symptoms and the clinical history reported by the patient or caregiver to infer the disease process, its etiology, disease progression and its response to treatment. Biomarkers quantify these changes, and can help to identify specific disease subtypes, such as those that are more likely to respond to a particular treatment. Our lab uses applied mathematics, computer science, data science, genomics, wet lab biology and patient registry studies to identify and test biomarkers. We aim to improve patient quantity and quality of life using biomarker-driven neurology.
Biography
A mathematician and computer scientist turned neuro-oncologist, Dr. Dhawan uses his background in data science to more accurately diagnose, treat and prognosticate neurological diseases. He holds appointments in Cleveland Clinic’s Lerner Research Institute and Taussig Cancer Center, where he is assistant staff in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. Dr. Dhawan’s research approach is interdisciplinary, having learned from experts in cancer biology, non-coding RNA biology, and evolutionary biology, alongside bioinformatics, data science, and applied mathematics. He has established the first suite of statistical metrics in a simple computational tool (sigQC) for the systematic evaluation of gene signature quality, now used by researchers worldwide for translational science. Dr. Dhawan collaborates with multiple researchers and physicians at Cleveland Clinic and other institutions on ongoing research projects for diseases including glioblastoma, glioma, meningioma, PTEN hamartoma tumor syndrome, tuberous sclerosis complex and leptomeningeal carcinomatosis.
Education & Professional Highlights
Appointed: 2023
Education & Fellowships
- Residency, Neurology: Cleveland Clinic (end 2022)
- Fellowship, Neuro-Oncology: Cleveland Clinic (end 2023)
- MD: Queen's University, Kingston, Ontario (2016)
- DPhil, Oncology: University of Oxford, Oxford, Oxfordshire (2017)
Honors & Awards
- 2024 – 2027 Early Stage Clinician Scientist Career Development Award, Neurological Institute, Cleveland Clinic
- 2023 - 2025 Clinical Research Training Scholarship, American Academy of Neurology
- 2022 - 2024 PTEN Research Young Investigator Award, Developmental Synaptopathies Consortium
- 2022 - Futures in Neurologic Research Scholarship, American Academy of Neurology
- 2016 – 2018 - Clarendon Fund Scholarship, Oxford University Press
- 2016 – 2018 - DPhil Prize Studentship, Cancer Research UK
- 2014 – 2015 - Bracken Scholarship in Medicine, Queen's University
Ongoing Memberships
- 2023 – present: Editorial Board Member, npj Genomic Medicine
- 2023 – present: Member, Society for Neuro-Oncology
- 2018 – present: Member, American Academy of Neurology
Research
Overview
Neurogenetic and neuro-oncologic conditions remain poorly understood, are individually rare and are clinically heterogeneous. Our lab’s mission is to advance care for neurological diseases and neurogenetic disorders using experimental biology, computational genomics, and mathematical modeling. Our multi-faceted approach to these diseases, we hope, will reveal reliable, readily implementable, mechanistic biomarkers for clinical translation. Our overarching vision is to extend patient quality and quantity of life, with evidence-based interventions in neurologic disease.
Neurogenetic and neuro-oncologic conditions remain poorly understood, are individually rare, and are clinically heterogeneous. Our lab’s mission is to advance care for neurological diseases and neurogenetic disorders using experimental biology, computational genomics, and mathematical modeling. Our multi-faceted approach to these diseases, we hope, will reveal reliable, readily implementable, mechanistic biomarkers for clinical translation. Our overarching vision is to extend patient quality and quantity of life, with evidence-based interventions in neurologic disease.
Gene signatures and non-coding RNA
The genomic revolution has provided incredibly detailed mechanistic insights into how individual cells behave in cancers, and how these patterns of activity drive disease. Understanding these large genomic datasets has relied on gene signatures, patterns of gene expression that indicate a phenotype of interest. Gene signatures have been developed for myriad biological phenomena: prognosis, cellular state, and diagnosis. However, most published gene signatures have not shown biological or clinical relevance outside the original datasets from which they were derived. We seek to identify new gene signatures, and new methods of developing gene signatures, with clinical relevance to bring these powerful tools to the clinic to help physicians more effectively prognosticate and treat disease. Specifically, we are interested in how non-coding RNA expression may function as a biomarker for neurological disorders. miRNA and circular RNA (circRNA) signatures may be detected readily in various biofluids and may help diagnose neurologic diseases earlier than alternative methods. We seek to identify specific miRNA and circRNA signatures that can function as potential diagnostic and therapeutic markers, using cerebrospinal fluid, blood, and tissue assays.
SigQC is an R package for the quality control assessment of gene signatures.
Disease risk assessment and prediction
We have broad collaborations with the goal of developing risk models for complications and disease progression. By combining genomic profiling, imaging, and clinical data, we can identify predictors for specific outcomes or disease subtypes. We also seek to use wearable devices in patient care to better understand how disease impacts function, and whether continuous remote monitoring, in diseases like glioblastoma, can improve outcomes and care.
Clinical care for rare neurologic disorders
A further focus of our lab is the care for individuals with rare neurologic disorders. Dr. Dhawan has been involved in the care for individuals with PTEN hamartoma tumor syndrome, a rare genetic disorder leading to a predisposition towards tumors and neurodevelopmental challenges. The expanding spectrum of neurologic challenges faced by individuals with PTEN hamartoma tumor syndrome is a strong interest of the lab, and we have helped lead the development of clinical care guidelines for the management of neurologic features of this condition.
Climate change and neurologic disease
Our lab has been among the first to comprehensively characterize the associations between climate and neurologic health. As a leader in this space, and as the climate changes, we seek to frame priorities for future adaptation of neurologic care, improve study methodology to better understand climate and neurologic health, and understand biological mechanisms of how neurologic health and climate are interrelated.
Our Team
Selected Publications
View publications for Andrew Dhawan, MD, DPhil, FRCPC
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dhawan Andrew, Kumar Harshita, Huang Honglian, Gupta Ajay. Phenotypic clustering in tuberous sclerosis complex reveals four distinct disease trajectories. Brain. 2025. 39982781.
Dhawan Andrew, Baitamouni Sarah, Liu Darren, Yehia Lamis, Eng Charis. Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group. Clin Cancer Res. 2025. 39937242.
Dhawan Andrew. Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. Nat Cell Biol. 2025. 39805921.
Hong Ellen S, Wang Sabrina Z, Ponti András K, Hajdari Nicole, Lee Juyeun, Mulkearns-Hubert Erin E, Volovetz Josephine, Kay Kristen E, Lathia Justin D, Dhawan Andrew. miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma. Neurooncol Adv. 2024. 39582810.
Liu Darren, Yehia Lamis, Dhawan Andrew, Ni Ying, Eng Charis. Protocol for analyzing plasma cell-free DNA fragment end motifs from ultra-low-pass whole-genome sequencing. STAR Protoc. 2024. 39368093.
Dhawan Andrew, Baitamouni Sarah, Liu Darren, Eng Charis. Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review. Neurology. 2024. 39250745.
Jarmula Jakub, Lee Juyeun, Lauko Adam, Grabowski Matthew M, Dhawan Andrew, Chen Peiwen, Lathia Justin D. Macrophage migration inhibitory factor as a therapeutic target in neuro-oncology: A review. Neurooncol Adv. 2024. 39233830.
Haddad Eliot N, Kumar Pranav, Shearn-Nance Galen, Kharal G Abbas, Dhawan Andrew. Clinical Approach to Genetic Cerebral Arteriopathy in the Adult Patient With Ischemic Stroke. Neurol Genet. 2024. 39176127.
Rilinger Ryan G, Guo Lydia, Sharma Akshay, Volovetz Josephine, Thompson Nicolas R, Grabowski Matthew, Lobbous Mina, Dhawan Andrew. Tumor-related epilepsy in high-grade glioma: a large series survival analysis. J Neurooncol. 2024. 39102118.
Hong Ellen S, Wang Sabrina Z, Ponti András K, Hajdari Nicole, Lee Juyeun, Mulkearns-Hubert Erin E, Volovetz Josephine, Kay Kristen E, Lathia Justin D, Dhawan Andrew. miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma. bioRxiv. 2024. 38559056.
Dhawan Andrew, Baitamouni Sarah, Liu Darren, Busch Robyn, Klaas Patricia, Parikh Sumit, Hsich Gary E, Eng Charis. Exploring the neurological features of individuals with germline PTEN variants: A multicenter study. Ann Clin Transl Neurol. 2024. 38501559.
Ranjan Surabhi, Lobbous Mina, Dhawan Andrew. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer. 2024. 38288941.
Liu Darren, Yehia Lamis, Dhawan Andrew, Ni Ying, Eng Charis. Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome. Cell Rep Med. 2024. 38242121.
Dhawan Andrew, Eng Charis. Is the gene mutation associated with thrombosis? Cleve Clin J Med. 2023. 37914198.
Scarborough Jessica A, Dhawan Andrew, Scott Jacob G. Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. NPJ Precis Oncol. 2023. 37076665.
Dhawan Andrew, Yeaney Gabrielle, Lathia Justin D. EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers (Basel). 2023. 36765632.
Ahluwalia Manmeet S, Peereboom David M, Dhawan Andrew. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023. 36521103.
Louis Shreya, Carlson Alise K, Suresh Abhilash, Rim Joshua, Mays MaryAnn, Ontaneda Daniel, Dhawan Andrew. Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice: A Scoping Review. Neurology. 2023. 36384657.
Dhawan Andrew. Machine Learning Using Gene-Sets to Infer miRNA Function. Adv Exp Med Biol. 2022. 36352216.
Dhawan Andrew, Peereboom David M, Stevens Glen Hj. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma. CNS Oncol. 2022. 35819008.
Weaver Davis T, Scarborough Jessica, Dhawan Andrew, Scott Jacob G. Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma. PLoS Comput Biol. 2021. 34662337.
Dhawan Andrew. Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful? Biomark Med. 2021. 34514843.
Weaver Davis T, Gopalakrishnan Vishhvaan, Card Kyle J, Crozier Dena, Dhawan Andrew, Dinh Mina N, Dolson Emily, Farrokhian Nathan, Hitomi Masahiro, Ho Emily, King Eshan S, Cadnum Jennifer L, Donskey Curtis J, Krishnan Nikhil, Kuzmin Gleb, Pelesko Julia, Scarborough Jessica A, Sedor Geoff, Scott Jacob G. UV decontamination of personal protective equipment with idle laboratory biosafety cabinets during the COVID-19 pandemic. PLoS One. 2021. 34310599.
Dhawan Andrew. Mathematical Modeling of ceRNA-Based Interactions. Methods Mol Biol. 2021. 34165711.
Louis Shreya, Dhawan Andrew, Newey Christopher, Nair Dileep, Jehi Lara, Hantus Stephen, Punia Vineet. Continuous electroencephalography characteristics and acute symptomatic seizures in COVID-19 patients. Clin Neurophysiol. 2020. 32949985.
Scarborough Jessica A, McClure Erin, Anderson Peter, Dhawan Andrew, Durmaz Arda, Hitomi Masahiro, Scott Jacob G. Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma. iScience. 2020. 32623338.
Scott Jacob. Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Sci Rep. 2020. 32576885.
A. Dhawan, H. Kumar, H. Huang, and A. Gupta. Phenotypic clustering in tuberous sclerosis complex reveals four distinct disease trajectories. Brain. (2025).
A. Dhawan, S. Baitamouni, D. Liu, L. Yehia, K. Anthony, A. McCarther, M. Tischkowitz, S. P. MacFarland, J. Ngeow, N. Hoogerbrugge, and C. Eng. Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumour Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group. Clinical Cancer Research. (2025).
R. Szmyd, S. Casolin, L. French, A. G. Manjon, M. Walter, L. Cavalli, C. B. Nelson, S. G. Page, A. Dhawan, E. Hau, H. A. Pickett, H. E. Gee, and A. J. Cesare. Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. Nature Cell Biology. (2025).
R. Kaur, N. Gupta, and A. Dhawan. Astrocyte plasticity shapes brain metastasis progression through tumor-astrocyte crosstalk. Cancer Heterogeneity and Plasticity. (2025).
N. Das, S. Bhat, P. Fugo, and A. Dhawan. miRNA as neuro-oncologic therapeutics: a narrative review. Molecular Therapy. (2024).
E. S. Hong, S. Z. Wang, A. K. Ponti, N. Hajdari, J. Lee, E. E. Mulkearns-Hubert, J. Volovetz, K. E. Kay, J. D. Lathia, and A. Dhawan. miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma. Neuro-Oncology Advances. (2024).
D. Liu, L. Yehia, A. Dhawan, Y. Ni, and C. Eng. Protocol for analyzing plasma cell-free DNA fragment end motifs from ultra-low-pass whole-genome sequencing. STAR protocols . (2024).
A. Dhawan, S. Baitamouni, D. Liu, and C. Eng. Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review. Neurology. (2024).
E. N. Haddad, P. Kumar, G. Shearn-Nance, G. A. Kharal, and A. Dhawan. Clinical Approach to Genetic Cerebral Arteriopathy in the Adult Patient With Ischemic Stroke. Neurology: Genetics. (2024).
J. Jarmula, J. Lee, A. Lauko, P. Rajappa, M. M. Grabowski, A. Dhawan, P. Chen, R. Bucala, M. A. Vogelbaum, and J. D. Lathia. Macrophage Migration Inhibitory Factor as a Therapeutic Target in Neuro-Oncology: A Review. Neuro-Oncology Advances. (2024).
R. G. Rilinger, L. Guo, A. Sharma, J. Volovetz, N. R. Thompson, M. M. Grabowski, M. Lobbous, and A. Dhawan. Tumor-related epilepsy in high-grade glioma: a large series survival analysis. Journal of Neuro-Oncology. (2024).
A. Dhawan, S. Baitamouni, D. Liu, R. Busch, P. Klaas, T. W. Frazier, S. Srivastava, S. Parikh, G. E. Hsich, N. R. Friedman, D. M. Ritter, A. Y. Hardan, J. A. Martinez-Agosto, M. Sahin, and C. Eng. Exploring the neurological features of individuals with germline PTEN variants: A multicenter study. Annals of Clinical and Translational Neurology. (2024).
S. Ranjan, D. Leung, A. P. Ghiaseddin, J. W. Taylor, M. Lobbous, A. Dhawan, J. A. Budhu, E. Coffee, K. Melnick, S. A. Chowdhary, C. Lu-Emerson, S. C. Kurz, J. E. Burke, K. Lam, M. P. Patel, E. M. Dunbar, N. A. Mohile, and K. B. Peters. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer. (2024).
D. Liu, L. Yehia, A. Dhawan, Y. Ni, and C. Eng. Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome. Cell Reports Medicine. (2024).
J. Doan and A. Dhawan. Neurology and climate change: what we know and where we are going. The Journal of Climate Change and Health. (2023).
A. Dhawan and C. Eng. Is the MTHFR gene mutation associated with thrombosis?. Cleveland Clinic Journal of Medicine. (2023).
J. A. Scarborough, S. A. Eschrich, J. Torres-Roca, A. Dhawan, J. G. Scott. Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. NPJ Precision Oncology. (2023).
A. Dhawan, V. S. K. Manem, G. Yeaney, J. D. Lathia, and M. S. Ahluwalia. EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers. (2023).
M. S. Ahluwalia, D. A. Reardon, A. P. Abad, W. T. Curry, E. T. Wong, S. A. Figel, L. L. Mechtler, D. M. Peereboom, A. D. Hutson, H. G. Withers, S. Liu, A. N. Belal, J. Qiu, K. M. Mogensen, S. S. Dharma, A. Dhawan, M. T. Birkemeier, D. M. Casucci, M. J. Ciesielski, and R. A. Fenstermaker. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. (2022).
S. Louis, A. K. Carlson, A. Suresh, J. Rim, M. Mays, D. Ontaneda, and A. Dhawan. Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice: A Scoping Review. Neurology. (2022).
A. Dhawan, D. M. Peereboom, and G. H. J. Stevens. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma. CNS Oncology. (2022).
D. T. Weaver, K. I. Pishas, D. Williamson, J. Scarborough, S. L. Lessnick, A. Dhawan, and J. G. Scott. Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma. PLoS Computational Biology. (2021).
A. Dhawan. Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful?. Biomarkers in Medicine. (2021).
D. T. Weaver, B. D. McElvany, V. Gopalakrishnan, K. J. Card, D. Crozier, A. Dhawan, M. Dinh, E. Dolson, N. Farrokhian, M. Hitomi, E. Ho, T. Jagdish, E. S. King, J. L. Cadnum, C. J. Donskey, N. Krishnan, G. Kuzmin, J. Li, J. Maltas, J. Mo, J. Pelesko, J. A. Scarborough, G. Sedor, E. Tian, G. C. An, S. A. Diehl, and J. G. Scott. UV decontamination of personal protective equipment with idle laboratory biosafety cabinets during the COVID-19 pandemic. PLoS One (2021).
S. Louis, A. Dhawan, C. Newey, D. Nair, L. Jehi, S. Hantus, and V. Punia. Continuous electroencephalography characteristics and acute symptomatic seizures in COVID-19 patients. Clinical Neurophysiology. (2020).
J. A. Scarborough, E. McClure, P. Anderson, A. Dhawan, A. Durmaz, S. L. Lessnick, M. Hitomi, and J. G. Scott. Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing’s Sarcoma. iScience. (2020).
A. Dhawan, J. G. Scott, P. Sundaresan, M. Veness, S. Porceddu, E. Hau, A. L. Harris, F. M. Buffa, and H. E. Gee. Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. Scientific Reports. (2020).
R. Vander Velde, N. Yoon, V. Marusyk, A. Durmaz, A. Dhawan, D. Miroshnychenko, D. LozanoPeral, B. Desai, O. Balynska, J. Poleszhuk, L. Kenian, M. Teng, M. Abazeed, O. Mian, A. C. Tan, E. Haura, J. G. Scott, and A. Maruysk. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nature Communications. (2020).
N. Aherne, A. Dhawan, J. Scott, and H. Enderling. Mathematical oncology and its application in non melanoma skin cancer? A primer for radiation oncology professionals. Oral Oncology. (2020).
A. Goldman, J. Smalley, M. Mistry, H. Krenzlin, H. Zhang, A. Dhawan, B. Caldarone, S. J. Moss, D. A. Silbersweig, S. E. Lawler, and I. M. Braun. A computationally inspired in-vivo approach identifies a link between amygdalar transcriptional heterogeneity, socialization and anxiety. Translational Psychiatry. (2019).
A. Goldman, S. Khiste, E. Freinkman, A. Dhawan, B. Majumder, J. Mondal, A. B. Pinkerton, E. Eton, R. Medhi, V. Chandrasekar, M. M. Rahman, T. Ichimura, K. S. Gopinath, P. Majumder, M. Kohandel, and S. Sengupta. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Science Signaling. (2019).
A. Dhawan, A. Barberis, W.C. Cheng, E. Domingo, C. West, T. Maughan, J. G. Scott, A. L. Harris, F. M. Buffa Guidelines for using sigQC for systematic evaluation of gene signatures. Nature Protocols. (2019).
J. G. Scott, A. Dhawan, A. Hjelmeland, J. Lathia, A. Chumakova, M. Hitomi, A. G. Fletcher, P. K. Maini, and A. R. A. Anderson Recasting the cancer stem cell hypothesis: unification using a continuum model of microenvironmental forces. Current Stem Cell Reports. (2019).
A. Dhawan, J. G. Scott, A. L. Harris, and F. M. Buffa Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nature Communications. (2019).
A. Dhawan, A. L. Harris, F. M. Buffa, and J. G. Scott Endogenous miRNA sponges mediate the generation of oscillatory dynamics for a non-coding RNA network. Journal of Theoretical Biology. (2019).
R. R. Wadhwa, D. F. K. Williamson, A. Dhawan, and J. G. Scott TDAstats: R pipeline for computing persistent homology in topological data analysis. Journal of Open Source Software. (2018).
A. Dhawan Investigating small non-coding RNA regulating the hallmarks of cancer. DPhil Thesis. (2018).
A. Dhawan and J. G. Scott Evading Therapeutic Resistance Through Collateral Sensitivity: A Paradigm Shift?. Oncology Times (2017).
J. P. Taylor-King, E. Baratchart, A. Dhawan, E. A. Coker, I. Hansine Rye, H. Russnes, S. J. Chapman, D. Basanta, and A. Marusyk Simulated Ablation for Detection of Cells Impacting Paracrine Signalling in Histology Analysis. Mathematical Medicine and Biology (2017).
V. Manem* and A. Dhawan* Modeling recurrence and second cancer risks induced by proton therapy. Mathematical Medicine and Biology (2017).
A. Dhawan, D. Nichol, F. Kinose, M. E. Abazeed, A. Marusyk, E. B. Haura, and J. G. Scott. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutant non-small cell lung cancer. Scientific Reports (2017).
R. Woolnough, A. Dhawan, K. Dow, and J. S. Walia. Are patients with Loeys-Dietz syndrome misdiagnosed with Beals syndrome?. Pediatrics (2017).
S. Tonekaboni*, A. Dhawan*, and M. Kohandel. Mathematical modeling of plasticity and phenotype switching in cancer cell populations. Mathematical Biosciences (2016).
A. Dhawan, A. Fletcher, and T. Graham. Computational modelling predicts optimal prognostic biomarkers for cancer risk in premalignant disease. Cancer Prevention Research (2016).
A. Dhawan*, S. Tonekaboni*, J. Taube*, S. Hu, N. Sphyris, S. A. Mani, and M. Kohandel. Mathematical modelling of phenotypic plasticity and conversion to a stem-cell state under hypoxia. Scientific Reports (2016).
A. Goldman, B. Majumder, A. Dhawan, S. Ravi, D. Goldman, M. Kohandel, P. K. Majumder, and S. Sengupta. Sequential administration of anti-cancer drugs overcomes adaptive resistance by targeting a vulnerable transition cell state during drug-induced phenotypic plasticity. Nature
Communications (2015).
A. Dhawan, K. Kaveh, M. Kohandel, and S. Sivaloganathan. Stochastic model for TCP: effects of cell cycle and (a)symmetric proliferation. Theoretical Biology and Medical Modelling (2014).
V. Manem*, A. Dhawan*, M. Kohandel, and S. Sivaloganathan. Efficacy of dose escalation on TCP, recurrence and second cancer risks: a mathematical study. British Journal of Radiology (2014).
A. Dhawan, M. Kohandel, R. Hill, and S. Sivaloganathan. Tumour control probability and cancer stem cells hypothesis. PLoS One (2014).
A. Dhawan, A. Hamadeh, and B. Ingalls. Designing synchronization protocols in networks of coupled nodes under uncertainty. Preceedings of the IEEE American Control Conference (2012).
* Co-first authors
Careers
We are always seeking talented, excited, and driven individuals to join our lab. We value diversity, equity, and inclusion, and I am personally committed to using science to make the world a fairer, better place. Graduate students and postdoctoral candidates are welcome to email Dr. Dhawan with a CV, statement of interest, and three references for consideration.
Research News
The study links specific TSC1/2 gene mutations to distinct disease trajectories to help guide patient care and surveillance for this multi-faceted disease.
The microRNA (miRNA) is involved in negative gene regulation and blocks cancer gene expression twice as much in XX females compared to XY males